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Abstract: Fentanyl is a strong opioid analgesic, which is commonly used in the form of a 
transdermal patch for the treatment of chronic cancer pain. An intranasal route of fentanyl 
administration is a novel treatment for breakthrough cancer pain (BTCP). The prevalence, 
assessment, and management of BTCP is outlined in this paper, and basic pharmacodynamic 
and pharmacokinetic properties, dosing guidelines, and clinical experience with the use of 
intranasal fentanyl in this indication are discussed. Intranasal fentanyl is an attractive and 
convenient mode of BTCP treatment in opioid-tolerant patients due to its quick onset and 
short duration of action, noninvasive administration route, high bioavailability, and avoidance 
of a hepatic first-pass effect. Until now, few clinical trials have been conducted with intranasal 
fentanyl, but all have confirmed its usefulness and acceptability in BTCP treatment. Intranasal 
fentanyl may be used in opioid-tolerant patients without nasal pathologies. The dose should be 
titrated in each patient regardless of the regular opioid dose administered. Future studies should 
compare intranasal fentanyl with other fentanyl formulations used for BTCP management, and 
with analgesia, adverse effects, and quality of life taken into consideration.
Keywords: adverse effects, analgesia, breakthrough pain, intranasal fentanyl, opioid   analgesics, 
treatment
Introduction
In patients with cancer pain of moderate to severe intensity, treatment is based on 
regular administration of opioid analgesics and adjuvant analgesics (coanalgesics) for 
effective pain relief. However, in spite of this regular treatment, an exacerbation of pain 
may appear, and is known as “breakthrough” pain. Breakthrough cancer pain (BTCP) 
is defined as a transitory exacerbation of pain to greater than moderate intensity, which 
occurs on a baseline pain of moderate intensity or less in a patient receiving opioid 
therapy.1 The term “breakthrough” pain was coined by Hilgier in Poland.2
Prevalence and assessment of BTCP
The prevalence of BTCP in patients admitted to a hospice was assessed in a 
  prospective survey. Among 414 consecutive admissions, 33 patients were confused 
and too unwell to take part in the study, 136 patients were pain-free, and 245 patients 
reported 404 pains (range 1–5 per patient). Of the latter patients, 218 (89%) had 
BTCP and identified 361 pains (range 1–5 per patient). BTCP was classified as 
somatic (46%), visceral (30%), neuropathic (10%), or of mixed etiology (16%). 
Thirty-eight percent of pains were severe or excruciating. The average number of 
breakthrough pain   episodes was 7 (range 1–14), and 49% of pain episodes occurred Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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suddenly. Most (59%) were unpredictable and 72% lasted 
for more than 30 minutes. Among the patients surveyed, 
75% were dissatisfied with their pain relief.3
In another observational cross-sectional study conducted 
in different settings (home and outpatient/inpatient units), the 
prevalence of BTCP in Catalonia, Spain, was determined in 
oncology patients treated by palliative care teams. BTCP was 
reported by 163 (41%) of 387 patients in this study. A total 
of 244 episodes (mean 1.5 episodes/patient/day) of mean 
intensity 7.3 ± 2.0 compared with 2.9 ± 2.7 for persistent pain 
(both 0–10 scales) was reported. Morphine was used to treat 
52% of the episodes, while 25% were untreated.4
In a prospective study of 63 cancer patients who reported 
moderate pain or less for more than 12 hours daily and had 
received stable opioid dosing for a minimum of two   consecutive 
days, 41 (64%) reported severe or excruciating BTCP. Fifty-
one different pains were described (median four pains per day, 
range 1–3600). Twenty-two (41%) pains were paroxysmal in 
onset, and the remainder was of more gradual onset. Duration 
of pain varied from seconds to hours (median 30 minutes, range 
1–240 minutes). Fifteen (29%) of the pains were related to the 
fixed opioid dose, occurring solely at the end of the dosing 
interval (currently not classified as BTCP). Twenty-eight (55%) 
of the pains were precipitated and, of these, 22 were caused by 
an action of the patient (incident pain) and six were associated 
with a nonvolitional precipitant. The pathophysiology of the 
pain was believed to be somatic in 17 (33%), visceral in 10 
(20%), neuropathic in 14 (27%), and mixed in 10 (20%) of 
cases. Pain was related to the tumor in 42 (82%), the effects of 
therapy in seven (14%), and neither in two (4%) cases.1
In a cross-sectional survey, inpatients with cancer completed 
several instruments to assess pain and mood (  Memorial Pain 
Assessment Card), pain-related interference with function 
(Brief Pain Inventory, BPI), depressed mood (Beck Depres-
sion Inventory), and anxiety (Beck Anxiety Inventory). Of 178 
eligible patients, 164 (92.2%) met the criteria for controlled 
baseline pain. The median age was 50.6 (range 26–77) years. 
Seventy-five percent of the patients had metastases and the 
majority had mixed nociceptive-neuropathic pain. The median 
Karnofsky score was 60 (range 40–90). Eighty-four (51.2%) 
patients had experienced BTCP during the previous day. The 
median number of episodes was six (range 1–60) and the median 
interval from onset to peak was three minutes (range one second 
to 60 minutes). Two-thirds of patients (61.7%) could identify 
precipitants (movement 20.4%, end-of-dose failure 13.2%), 
and pain was unpredictable in most cases (78.2%). Patients 
with BTCP had more intense (P , 0.001) and more frequent 
(P , 0.01) background pain than patients without BTCP. Greater 
pain-related functional impairment was also associated with 
BTCP (BPI, P , 0.001), as well as worse mood (visual analog 
scale, P , 0.05, Beck Depression Inventory, P , 0.001) and 
greater anxiety (Beck Anxiety Inventory, P , 0.001). Multivari-
ate analysis confirmed that BTCP independently contributed to 
impaired functioning and psychologic distress.5
In a prospective cross-sectional study, 1095 patients with 
cancer pain were evaluated by 58 clinicians from 24 countries 
using patient-rated items from the BPI and observer-rated mea-
sures, including demographic and tumor-related data, occur-
rence of BTCP, and responses on checklists for pain syndromes 
and pathophysiologies. The clinicians reported BTCP in 64.8% 
of patients. Physicians from   English-speaking countries were 
significantly more likely to report BTCP than physicians from 
other countries. BTCP was associated with higher pain scores 
and functional interference on the BPI. Multivariate analysis 
showed an independent   association of BTCP with the presence 
of more than one pain, a vertebral pain syndrome, pain due to 
plexopathy, and an English-speaking country.6
Assessment of BTCP is crucial to its appropriate and effec-
tive management. The etiology, characteristics, and mechanisms 
of BTCP should be elucidated.7 The temporal course, severity, 
and impact of BTCP on the patient’s daily activities and qual-
ity of life should be assessed, as well as the psychologic and 
social burden of BTCP. A detailed   history and thorough clinical 
examination should be performed. Assessment of background 
pain relief is also a very   important step in effective management 
of BTCP.8 Assessment of BTCP is similar to the evaluation of 
baseline pain because no specific instrument for BTCP assess-
ment exists. BTCP evaluation is based on a detailed history 
Table 1 Questions asked for the assessment of breakthrough 
pain. Copyright © 2009. Adapted with permission from Davies AN, 
Dickman A, Reid C, Stevens AM, Zeppetella G. The management 
of  cancer-related  breakthrough  pain:  Recommendations  of 
a  Task  Group  of  the  Science  Committee  of  the  Association 
for Palliative Medicine of Great Britain and ireland. Eur J Pain. 
2009;13:331–338
  1. Onset of pain
  2. Frequency of pain
  3. Site of pain
  4. Radiation of pain
  5. Quality (character of pain)
  6. intensity (severity) of pain
  7. Duration of pain
  8. exacerbating factors
  9. Relieving factors
10. Response to analgesics
11. Response to other interventions
12. Associated symptoms
13. interference with daily living.Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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(Table 1),9 thorough clinical examination, and, if doubts exist 
as to the cause of pain, radiologic imaging may be helpful.10
Management of BTCP
Several expert recommendations have addressed the issue 
of guidelines for BTCP management.11–13 Generally, there 
are limited data based on randomized controlled studies, so 
only general recommendations have been proposed for the 
management of BTCP (Table 2).
BTCP may be classified into three subtypes, ie, non-
incident pain, incident pain, and end-of-dose failure. The 
latter cannot be considered as BTCP because it is associated 
with an   insufficient dose or too long an interval between 
  administration of analgesia. The management of end-of-dose 
pain is usually to increase the dose or to shorten the interval 
of regular analgesic administration to control the baseline 
pain. Nonincident pain is called spontaneous (“idiopathic”) 
pain, where pain episodes are not related to an identified 
precipitant, and so are unpredictable in nature.14 Incident pain 
is due to specific triggers, such as walking or movement in 
bed, and generally it is predictable (volitional incident pain). 
Predictable incident pain is best managed prophylactically. 
Incident pain associated with smooth muscle contraction or 
coughing is more difficult to predict (nonvolitional incident 
pain).12
The management of BTCP is based on the use of short-
acting formulations of opioids such as morphine, oxycodone, 
hydromorphone, buprenorphine, and methadone (rescue 
dose). In a prospective study of hospice inpatients with BTCP, 
the times to onset of pain relief after different rescue opioid 
analgesic administration were compared. Patients presented 
with, on average, 1.7 different types of breakthrough pain 
(range 1–4). The average number of breakthrough pains 
was four per day (range 1–8), and the average duration was 
35 minutes (range 15–60), with most occurring suddenly 
and unpredictably. Patients used morphine, oxycodone, 
hydromorphone, methadone, or oral transmucosal fentanyl 
citrate as rescue medication, and the average time to mean-
ingful pain relief following administration of analgesia was 
31 (range 5–75) minutes. No difference was found between 
morphine, oxycodone, and hydromorphone. Methadone 
appeared to work faster than morphine (P , 0.01), but no 
faster than oxycodone or hydromorphone, whereas oral 
transmucosal fentanyl citrate worked faster than morphine, 
oxycodone, hydromorphone, and methadone (P , 0.001).15 
In spite of a delayed analgesic effect of these drugs, their 
advantages include a huge clinical experience and ease of 
administration, usually by the oral route, which is especially 
useful for patients treated at home. However, the slow onset 
of analgesia (20–30 minutes) and delayed peak analgesia 
(60–90 minutes) often results in ineffective analgesia with a 
prolonged duration of effect (3–6 hours).12
Apart from the convenient oral route, other routes may be 
used to administer opioid analgesics for the treatment of BTCP. 
The intravenous route is very effective, although is used mostly 
in the hospital setting.16 The subcutaneous route of opioid 
administration is effective and may also be used at home.17 
Rectal administration may be considered,   especially in a liquid 
formulation which seems to have a shorter peak effect.18 However, 
this route may be inconvenient for many patients. Intrathecal 
administration of opioids, local anesthetics, and clonidine may 
also be considered.19 In some patients, treatment with nonopioid 
analgesics, such as paracetamol,20 nonsteroidal anti-inflammatory 
drugs,21 and bisphosphonates may be effective in incident bone 
pain.22 Ketamine in neuropathic or mixed neuropathic and 
bone pain syndromes may be administered.23 Severe BTCP 
not responding to high doses of intravenous morphine may be 
treated successfully with an intrathecal bolus of   levobupivacaine 
or sublingual ketamine.24 Radiotherapy may be beneficial in bone 
pain.25 Surgical and anesthetic techniques should be considered 
in patients with specific pain syndromes.26
Table 2 Recommendations for the management of cancer-related 
breakthrough pain. Copyright  © 2009. Adapted with permission 
from  Davies AN,  Dickman A,  Reid  C,  Stevens AM,  Zeppetella 
G.  The  management  of  cancer-related  breakthrough  pain: 
Recommendations of a Task Group of the Science Committee 
of the Association for Palliative Medicine of Great Britain and 
ireland. Eur J Pain. 2009;13:331–338
  1. Patients with pain should be assessed for the presence of BTCP
  2. Patients with BTCP should have the pain specifically assessed
  3.   The management of breakthrough cancer pain should be 
individualized
  4.   Consideration should be given to treatment of underlying cause  
of the pain
  5.   Consideration should be given to avoidance/treatment of 
precipitating factors of pain
  6.   Consideration should be given to modification of the background 
analgesic regimen/around the clock medication
  7.   Opioids are the rescue medication of choice in the management of 
breakthrough cancer pain episodes
  8.   The dose of opioid rescue medication should be determined by 
individual titration
  9.   Nonpharmacologic methods may be useful in the management of 
breakthrough cancer pain episodes
10.   Nonopioid analgesics may be useful in the management of 
breakthrough cancer pain episodes
11.   interventional techniques may be useful in the management of 
breakthrough cancer pain
12.   Patients with breakthrough cancer pain should have this pain 
specifically re-assessedCancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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Fentanyl in BTCP
A more recent method of BTCP management is use of 
rapid-onset opioids, including different formulations of 
fentanyl, ie, oral transmucosal fentanyl citrate, buccal 
fentanyl tablets, and intranasal fentanyl. The advantages of 
these new formulations are their quicker onset and shorter 
duration of action, which both fit the time profile of BTCP 
better because pain usually starts and intensifies quickly 
(in approximately three minutes) and lasts 30–60 min-
utes. However, limited data are available on the efficacy 
and tolerability of these newer preparations, and health 
professionals have limited familiarity with their use. The 
high cost of these new therapies should also be carefully 
considered.14
Fentanyl, a fenylpiperidine derivative, is a synthetic 
opioid analgesic, the chemical structure of which is similar 
to that of pethidine, and it has been used since 1959.27 Fen-
tanyl is a pure µ opioid receptor agonist, and is approxi-
mately 100-fold more potent than morphine.28 Because of 
its high lipid solubility, fentanyl is distributed in all human 
tissues and, in contrast with morphine, crosses the blood-
brain barrier easily and quickly, which explains its strong 
analgesic effect and lower intensity of the common adverse 
opioid effects associated with a central (nausea and vomit-
ing) and peripheral (constipation) mode of action.29,30 The 
drug is characterized by a short duration of analgesia (30–
60 minutes) after intravenous administration. In contrast 
with morphine, fentanyl does not induce histamine release. 
Fentanyl may induce chest wall rigidity, so transdermal 
fentanyl patches are not recommended for the treatment of 
patients with dyspnea,31,32 who are usually treated with 
morphine.33 However, several published case series have 
reported successful use of oral transmucosal fentanyl 
citrate34 or intranasal fentanyl in the treatment of 
breathlessness.35
Fentanyl is metabolized predominantly in the liver but 
also in the duodenum (at a mean rate which is approximately 
half that of hepatic metabolism) through cytochrome 
(CYP)3A4 to pharmacologically inactive metabolites (pre-
dominantly norfentanyl and hydroxyfentanyl), which are 
excreted in the urine.36 Because many drugs inhibit 
CYP3A4, and the enzyme activity differs significantly 
between individuals, numerous pharmacokinetic drug 
interactions are possible with fentanyl.37 Following intra-
venous administration, approximately 85% of fentanyl is 
found predominantly as metabolites in the urine within 
72 hours. In patients with renal or liver failure, the fentanyl 
dose should be adjusted due to the possibility of accumulation 
of fentanyl and its metabolites.38 Careful fentanyl dosing is 
recommended in older patients, who are usually more sus-
ceptible to the effects of opioid analgesics due to changes 
in protein binding ability, and in the distribution and elimi-
nation of drugs.
Intranasal fentanyl
Intranasal drugs should be administered in small volumes 
to avoid runoff into the pharynx. In adults, the nasal cavity 
volume is 15–20 mL and the surface area is 150–180 cm². 
A single administration volume in one nostril to avoid runoff 
of the drug to the pharynx is 150 µL. Different vehicles and 
additives may be required to obtain a therapeutically   effective 
dose in a small-volume solution, and some of these act as 
penetration enhancers.39
The high lipid solubility of fentanyl may play an important 
role in its good absorption through the nasal mucosa. For the 
intranasal route of fentanyl administration, the time to maximal 
plasma concentration is 13 minutes and the bioavailability is 
70%–90%.40 As a result of intranasal administration, the drug 
bypasses the liver, thereby avoiding the hepatic first-pass 
effect.41 The concomitant use of nasal mucosal decongestants 
should be avoided because these agents may decrease fentanyl 
bioavailability.42 In a single-dose, randomized, crossover, 
double-blind study conducted in healthy volunteers, a fentanyl 
dose of 0.054 mg/1.08 mL was administered to both nostrils. 
Time to peak concentration was five minutes after drug admin-
istration and the peak level was 0.29 ± 0.076 ng/mL, with a 
bioavailability of 71%.43 The pharmacokinetics of intranasal 
fentanyl spray were assessed in a randomized, open-label, 
two-period, crossover trial conducted in 19 patients with 
BTCP.44 Intranasal fentanyl spray was administered as a single 
dose in one nostril. Each dose was separated by at least 
48 hours. Mean fentanyl plasma concentrations increased in 
a dose-dependent manner, peaking for all doses at 9–15 min-
utes after intranasal fentanyl spray administration. Median 
times to peak concentration were 15, 12, and 15 minutes for 
the 50, 100, and 200 µg doses of intranasal fentanyl spray, 
respectively. Mean (±standard deviation) values for peak 
concentrations were 351 (±226), 595 (±400), and 1195 (±700) 
pg/mL, respectively, indicating dose proportionality. Six 
patients (31.6%) experienced adverse events during the treat-
ment period, the majority being mild in severity. Intranasal 
fentanyl appears to work faster than oral transmucosal fentanyl 
citrate or buccal fentanyl tablets, and the intranasal route may 
be used in patients who suffer from dry mouth and therefore 
cannot use either oral transmucosal fentanyl citrate or buccal 
fentanyl tablets.45Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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Intranasal fentanyl  
in postoperative pain
Several studies have been conducted in patients with 
  postoperative pain and have established the efficacy and 
safety of nasal fentanyl administration in both adults46,47 and 
in children.48,49 In a randomized, double-blind study, 
Striebel et al compared intranasal fentanyl spray with intra-
venous fentanyl in patients with pain following surgery for 
lumbar intervertebral disc protrusion.46 Twenty-two patients 
received six sprays of fentanyl 0.027 mg intranasally and 
placebo intravenously, and 20 patients received placebo 
intranasally and fentanyl 0.027 mg intravenously. Before 
the beginning of opioid titration and then every 10 minutes 
for at least one hour, pain was evaluated using a 101-point 
numeric rating scale and a verbal rating scale. In both groups, 
the doses were repeated every five minutes until patients 
were free of pain or refused further analgesics. All patients 
were satisfied with the pain relief achieved. The total fentanyl 
dose was 0.073 (range 0.027–0.162) mg in the intravenous 
group and 0.11 (range 0.027–0.243) mg in the intranasal 
group. The onset of action after intranasal fentanyl was 
nearly as rapid as that after intravenous titration. In both 
groups, pain intensity significantly decreased within 
10 minutes of drug administration, and pain   reduction was 
comparable in both groups. Only at the 10, 20, and 30-minute 
measurement points was the pain intensity significantly 
lower in the intravenous than in the intranasal group. One 
patient in the intravenous group showed a decrease in arterial 
  hemoglobin oxygen saturation to less than 90%. No other 
serious adverse effects were observed, and adverse events 
were similar in both patient groups and did not require ces-
sation of treatment. Local adverse effects in the nasal cavity 
were not observed.
In a prospective, randomized, double-blind, double-
dummy study, Toussaint et al compared fentanyl given as a 
25 µg intranasal bolus and 17.5 µg for intravenous patient-
controlled analgesia with a lockout interval of six minutes in 
48 patients on the day of surgery (orthopedic, abdominal, or 
thyroid).47 The first requested dose was doubled in both groups. 
Pain intensity and analgesia were assessed by a   101-point 
numeric rating scale and, together with vital   parameters, 
were measured at 11 time points over 240   minutes. Onset of 
analgesia and first reduction in pain intensity on the numeric 
rating scale occurred at 21 ± 11 (range 15–45) minutes in 
the intranasal group and at 22 ± 16 (range 15–90) minutes 
in the intravenous   patient-controlled analgesia group. Pain 
intensity was reduced from 55 ± 11 to 11 ± 10 in the intranasal 
group and from 53 ± 8 to 11 ± 6 in the   intravenous patient-
controlled analgesia group. Vital parameters remained 
stable and adverse effects were comparable in both groups. 
A judgment of “excellent” or “good” pain relief was given 
by 21 of 23 patients treated intranasally and 24 of 25 patients 
treated intravenously.
Intranasal fentanyl in BTCP
A few clinical studies have assessed the effects of intranasal 
fentanyl in the treatment of BTCP. Zeppetella reported two 
patients treated with nebulized and intranasal fentanyl for 
BTCP. Both patients had good pain relief without significant 
adverse effects.50 Zeppetella conducted a preliminary study with 
intranasal fentanyl citrate in cancer patients with nociceptive 
pain.51 Patients enrolled stayed at the inpatient unit and were 
treated with regularly administered opioids, ie, morphine in 11 
patients and transdermal   fentanyl in one patient. The rescue 
drug was a short-acting oral   morphine preparation. A single 
dose of intranasal fentanyl citrate 20 µg was used, with no pos-
sibility of dose titration. Of 12 patients enrolled, eight reported 
good or very good pain relief. Nine patients continued treatment 
with intranasal fentanyl citrate, including one patient who did 
not experience pain relief after drug administration. Treatment 
failure was observed in patients receiving higher equivalent 
morphine daily doses (120 mg or more) whereas responders 
to intranasal fentanyl citrate received lower morphine doses. 
The treatment was well tolerated with no significant systemic 
adverse effects. Nasal itching was observed in two patients 
which disappeared with repeated drug application. 
Kress et al investigated the efficacy and long-term 
tolerability of intranasal fentanyl spray 50–200 µg in the 
treatment of BTCP in opioid-tolerant patients in a double-
blind, randomized, placebo-controlled, crossover trial.52 
Patients were recruited from pain centers, anesthesiology 
departments, palliative care units, and oncology clinics in 
Austria, Denmark, France, Germany, and Poland. Eligible 
patients were adults with cancer receiving a stable dose of 
long-term opioid treatment for the control of background 
pain. Patients were treated at home with their effective dose 
of intranasal fentanyl spray (50, 100, or 200 µg) or placebo 
in a randomized sequence for three weeks, followed by 
a 10-month, open-label tolerability phase during which 
they received their effective dose of intranasal fentanyl 
spray. Patients were allowed to use their usual rescue 
medications. Pain was assessed on an 11-point numeric 
rating scale (0 = no pain, 10 = worst pain imaginable) with 
pain intensity difference (PID) at 10 minutes after drug 
administration. A total of 120 patients were enrolled and 
achieved an effective dose; 113 were randomized and 111 Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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were included in the intent-to-treat analysis set (intranasal 
fentanyl spray 50 µg 18 patients, 100 µg 48 patients, and 
200 µg 45 patients, and placebo 110 patients). The PID at 
10 minutes after intranasal fentanyl spray administration 
was two-fold greater than that after placebo (P , 0.001). 
The mean response rate with all three doses of intranasal 
fentanyl spray was 51.1% versus 20.9% with placebo. 
The prevalence of adverse effects was 22/111 (19.8%) during 
the efficacy period, and the most frequently reported adverse 
effects were nausea in five patients (4.5%) and vertigo in two 
(1.8%). No serious adverse effects were considered to be 
related to the study medication. In all, 108 patients entered 
the   extension period, with a mean duration of exposure to 
intranasal fentanyl spray of 134.9 days. The most common 
adverse event reported during this period was progression of 
underlying malignant disease in 55 (50.9%) patients, which 
was not considered to be treatment-related.
Mercadante et al compared the efficacy of intranasal 
fentanyl spray with that of oral transmucosal fentanyl citrate 
for the relief of BTCP in an open-label, crossover trial.53 
Adult cancer patients receiving stable background opioid 
treatment and experiencing BTCP episodes were recruited 
from 44 study centers in seven European countries (Austria, 
France, Germany, Italy, Poland, Spain, and the UK). Of the 196 
patients enrolled, 139 were randomized to receive intranasal 
fentanyl spray, followed by oral transmucosal fentanyl citrate, 
or vice versa. Patients were titrated to an effective dose of one 
agent (intranasal fentanyl spray 50, 100, or 200 µg, or oral 
transmucosal fentanyl citrate 200, 400, 600, 800, 1200, or 
1600 µg) to treat six BTCP episodes, then titration and treat-
ment were repeated with the other agent. The primary outcome 
was patient-recorded time to onset of meaningful pain relief. 
Secondary outcomes included PID at 10 and 30 minutes, sum 
of PID at 15 and 60 minutes, ease of administration, treatment 
preference, and relationship between background opioid dose 
and effective intranasal fentanyl spray dose.
Additional outcome measures included the proportions of 
episodes with $33% and $50% pain intensity reduction and 
PID at additional time points. Among the intention-to-treat 
population (n = 139), the median time to onset of meaning-
ful pain relief was 11 minutes for intranasal   fentanyl spray 
versus 16 minutes for oral transmucosal fentanyl citrate; 
65.7% of patients had a faster time to meaningful pain relief 
onset with intranasal fentanyl spray (P , 0.001). PID was 
significantly greater for intranasal fentanyl spray than for oral 
transmucosal fentanyl citrate from five minutes postdosing. 
Significantly more intranasal fentanyl spray-treated BTCP epi-
sodes achieved clinically important pain relief ($33% versus 
$50% pain intensity reduction) up to 30 minutes postdosing. 
The proportions of episodes treated with intranasal fentanyl 
spray and oral transmucosal fentanyl citrate achieving a pain 
intensity reduction of $33% at five minutes were 25.3% ver-
sus 6.6% (P , 0.001, respectively), and at 10 minutes were 
51.0% versus 23.6% (P , 0.001). The proportions of episodes 
treated with intranasal fentanyl spray and oral transmucosal 
fentanyl citrate achieving $50% pain intensity reduction at 
five minutes were 12.8% versus 2.1% (P , 0.001), and at 
10 minutes were 36.9% versus 9.7% (P , 0.001), respectively. 
Higher sum of PID scores at 15 and 60 minutes were achieved 
with intranasal fentanyl spray (P , 0.001). More patients 
preferred intranasal fentanyl spray to oral transmucosal fen-
tanyl citrate (P , 0.001), and more patients found it easy or 
very easy to use. Both treatments were well tolerated. In the 
safety population analysis (n = 139), 56.8% (n = 79) of patients 
experienced more than one adverse event during the trial. The 
only adverse effect that occurred in 5% or more patients in 
either treatment group was nausea. Among those patients who 
experienced serious adverse events (13.7%, n = 19), none were 
considered to be related to either study medication. There was 
a weak   correlation between effective intranasal fentanyl spray 
doses and background opioid doses.
Stam et al evaluated the cost effectiveness of intranasal 
fentanyl spray and oral transmucosal fentanyl citrate for 
the treatment of BTCP.54 A decision-analytic model was 
  developed to estimate the costs and benefits   associated with 
intranasal fentanyl spray and oral transmucosal fentanyl 
citrate. The model translated expected reduction in pain of 
BTCP episodes into resource use/cost savings and into   quality 
of life gains for an assumed remaining life expectancy of six 
months. Efficacy data were obtained from clinical trials and 
indirectly compared, adjusting for differences in placebo 
responses. With intranasal fentanyl spray, 63% of BTCP (95% 
confidence interval [CI] 51%–70%) was avoided, which was 
greater than with oral transmucosal fentanyl citrate (29%, CI 
17%–42%). Given the short life expectancy of these patients, 
this efficacy difference translated into a 0.055 gain in quality-
adjusted life years with intranasal   fentanyl spray relative to 
oral transmucosal   fentanyl citrate. Due to its greater efficacy, 
intranasal fentanyl spray is expected to reduce medical 
resource use and bring about greater cost savings than oral 
transmucosal fentanyl citrate. Despite the uncertainty of 
resource data, there is a greater than 99% probability that 
intranasal   fentanyl spray is cost-effective relative to oral 
transmucosal fentanyl citrate.
Vissers et al undertook an extended meta-analysis of six 
randomized, controlled trials that compared intranasal   fentanyl Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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spray with oral transmucosal fentanyl citrate,   buccal fentanyl 
tablets, and oral morphine for the treatment of BTCP.45 The 
endpoint was PID reported on a 10-point numeric rating scale 
up to 60 minutes after intake.   Intranasal fentanyl spray provided 
the greatest reduction in pain   relative to placebo, ie, PID was 
1.7 points (95% CI 1.4–1.9) at 15   minutes, 2.0 (1.6–2.3) at 
30 minutes, 2.0 (1.5–2.4) at 45 minutes, and 1.9 (1.5–2.4) at 
60   minutes. PIDs for oral transmucosal fentanyl citrate and 
buccal fentanyl tablets relative to placebo were 0.4 (0.0–0.8) 
and 0.5 (0.3–0.7), respectively, at 15 minutes. Both treatments 
provided a reduction in pain superior to placebo at other time 
points. Intranasal fentanyl spray displayed a more than 99% 
probability of providing the greatest pain reduction out of all 
interventions at 15 minutes after intake. This was maintained 
for any measured time point before 45 minutes when compared 
with buccal fentanyl tablets, and for any measured time point 
before 60 minutes when compared with oral transmucosal fen-
tanyl citrate. Only from 45 minutes onwards did oral morphine 
show a greater pain reduction than placebo.
Conclusion
Intranasal fentanyl is a promising option for the treatment of 
patients with BTCP, in spite of concerns of possible abuse, 
mostly in patients with chronic nonmalignant pain.55 It pro-
vides a convenient mode of breakthrough pain treatment in 
opioid-tolerant cancer patients due to a quick onset and short 
duration of action, which matches well the breakthrough pain 
pattern in most cancer patients with moderate to severe pain. 
The dose of intranasal fentanyl should be titrated regardless 
of the regular opioid dose administered. The advantages of 
intranasal fentanyl are its noninvasive administration route, 
high bioavailability with avoidance of an hepatic first-pass 
effect and high patient acceptability. In contrast with oral 
transmucosal fentanyl citrate and buccal fentanyl tablets, 
intranasal fentanyl may be recommended in the treatment 
of BTCP in patients with dry mouth. Although only a few 
clinical trials have been conducted with intranasal fentanyl in 
BTCP, all have confirmed its usefulness, and a meta-analysis 
has found that it works faster than oral transmucosal fentanyl 
citrate, buccal fentanyl tablets, or oral morphine.45 Intranasal 
fentanyl may be used in opioid-tolerant patients without nasal 
pathologies. Potential pharmacokinetic and pharmacodynamic 
drug interactions should be kept in mind when using this new 
mode of fentanyl delivery. The results of a preliminary study 
indicate the possibility of effective intranasal ketamine use 
in BTCP.56 Future studies should compare intranasal fentanyl 
with other fentanyl formulations for BTCP, evaluating anal-
gesia, adverse effects, and quality of life.
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